SignalFDA/Bio
GSK is expecting its cancer drug clinical pipeline to nearly double in 2027
GSK expects its cancer drug clinical pipeline to nearly double in 2027.
Context
What happened: GSK oncology chief Hesham Abdullah said the company has about 15 cancer assets in trials and could run 19 to 20 late-stage studies next year.
Key numbers: About 15 cancer assets in trials; 19 to 20 late-stage studies possible next year.
Why it matters: The expansion points to a larger late-stage oncology pipeline for GSK in 2027, based on the trial count cited by its oncology chief.
What changed
GSK oncology chief Hesham Abdullah said the company has about 15 cancer assets in trials and could run 19 to 20 late-stage studies next year.
Why it matters
The expansion points to a larger late-stage oncology pipeline for GSK in 2027, based on the trial count cited by its oncology chief.